Sangamo Therapeutics Ownership | Who Owns Sangamo Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Sangamo Therapeutics Ownership Summary


Sangamo Therapeutics is owned by 5.12% institutional investors, 2.08% insiders, and 92.80% retail investors. Vanguard group is the largest institutional shareholder, holding 3.94% of SGMO shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 2.51% of its assets in Sangamo Therapeutics shares.

SGMO Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockSangamo Therapeutics5.12%2.08%92.80%
SectorHealthcare Stocks 232.86%10.65%-143.51%
IndustryBiotech Stocks 382.13%10.41%-292.54%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Vanguard group12.00M3.94%$5.04M
Renaissance8.43M2.77%$3.54M
Blackrock4.70M2.61%$1.69M
Jacobs levy equity management2.95M1.64%$1.06M
Blackrock funding, inc. /de4.57M1.50%$1.92M
Millennium management2.74M1.31%$2.79M
Geode capital management3.87M1.27%$1.62M
Two sigma investments, lp2.48M0.96%$1.67M
Jane street group2.92M0.96%$1.23M
Two sigma advisers, lp2.11M0.82%$1.42M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Luminus management250.00K0.15%$168.35K
Diametric capital, lp359.01K0.09%$241.75K
Ikarian capital1.29M0.09%$871.82K
Wealth management associates315.80K0.05%$132.64K
Hedges asset management125.00K0.04%$52.50K
Sanders morris harris668.00K0.03%$164.93K
R squared89.87K0.01%$22.19K
Two sigma securities65.31K0.01%$43.98K
Meritage portfolio management227.00K0.01%$95.34K
Renaissance8.43M0.01%$3.54M

Top Buyers

HolderShares% AssetsChange
Jacobs levy equity management2.95M0.00%2.76M
Vanguard fiduciary trust2.31M0.00%2.31M
Two sigma investments, lp2.48M0.00%1.60M
Ubs group2.57M0.00%1.55M
Two sigma advisers, lp2.11M0.00%901.62K

Top Sellers

HolderShares% AssetsChange
Armistice capital---14.06M
Blackrock4.70M--8.57M
Acadian asset management---4.56M
Point72 asset management---2.00M
D. e. shaw1.17M0.00%-1.90M

New Positions

HolderShares% AssetsChangeValue
Vanguard fiduciary trust2.31M0.00%2.31M$570.64K
Diametric capital, lp359.01K0.09%359.01K$241.75K
Luminus management250.00K0.15%250.00K$168.35K
Vanguard global advisers154.06K-154.06K$38.05K
Hedges asset management125.00K0.04%125.00K$52.50K

Sold Out

HolderChange
Barclays-1.00
Headlands-5.00
Srs capital advisors-31.00
Td waterhouse canada-31.00
Gps wealth strategies group-100.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202537-68.91%15,567,844-75.13%50.86%15-72.73%8-60.00%
Sep 30, 202543-61.95%19,880,715-60.46%72.02%17-63.83%7-75.86%
Jun 30, 2025118-9.92%51,227,326-2.55%193.50%47-16.07%32-5.88%
Mar 31, 2025130-4.41%52,338,132-14.91%232.73%55-22.54%349.68%
Dec 31, 202413218.92%56,338,8180.73%273.75%6763.41%31-6.06%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard US Total Market Shares ETF5.65M2.51%1.00
Wasatch Ultra Growth5.59M2.28%1.06M
Vanguard Total Stock Mkt Idx Inv7.96M1.92%-
SPDR® S&P Biotech ETF3.73M1.75%-22.75K
Wasatch Micro Cap2.34M1.12%-3.31M
Vanguard Institutional Extnd Mkt Idx Tr4.46M1.08%693.29K
Vanguard Strategic Small-Cap Equity Inv1.71M0.82%-
Vanguard Explorer Inv1.40M0.67%-
Fidelity Extended Market Index2.10M0.51%321.57K
Schwab US Small-Cap ETF™1.80M0.43%-131.00

Recent Insider Transactions


DateNameRoleActivityValue
Apr 22, 2026Davis Gregory D Head of Research & TechnologySell$17.69K
Apr 21, 2026Dubois-Stringfellow Nathalie SVP-CHIEF DEVELOPMENT OFFICERSell$89.18K
Sep 26, 2023BIOGEN INC.-Sell$3.00M
Aug 29, 2022BIOGEN INC.-Sell$2.13M
Aug 29, 2022Biogen MA Inc. Sell$526.52K

Insider Transactions Trends


DateBuySell
2026 Q2-2
2026 Q1--
2025 Q4--
2025 Q3--
2025 Q2--

SGMO Ownership FAQ


Who Owns Sangamo Therapeutics?

Sangamo Therapeutics shareholders are primarily institutional investors at 5.12%, followed by 2.08% insiders and 92.80% retail investors. The average institutional ownership in Sangamo Therapeutics's industry, Biotech Stocks , is 382.13%, which Sangamo Therapeutics falls below.

Who owns the most shares of Sangamo Therapeutics?

Sangamo Therapeutics’s largest shareholders are Vanguard group (12M shares, 3.94%), Renaissance (8.43M shares, 2.77%), and Blackrock (4.7M shares, 2.61%). Together, they hold 9.32% of Sangamo Therapeutics’s total shares outstanding.

Does Blackrock own Sangamo Therapeutics?

Yes, BlackRock owns 2.61% of Sangamo Therapeutics, totaling 4.7M shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 1.69M$. In the last quarter, BlackRock decreased its holdings by -8.575M shares, a -64.58% change.

Who is Sangamo Therapeutics’s biggest shareholder by percentage of total assets invested?

Luminus management is Sangamo Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.15% of its assets in 250K Sangamo Therapeutics shares, valued at 168.35K$.

Who is the top mutual fund holder of Sangamo Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Sangamo Therapeutics shares, with 2.51% of its total shares outstanding invested in 5.65M Sangamo Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools